Pacific Biosciences of California, Inc.

Total Valuation

Pacific Biosciences of California, Inc. carries a market capitalization of 419.31M, placing it among publicly traded companies globally. Its enterprise value stands at 991.41M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Pacific Biosciences of California, Inc. currently has 310.81M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 3.21, and the price-to-book ratio stands at -15.72.

Enterprise Valuation

Financial Position

Pacific Biosciences of California, Inc. maintains a current ratio of 4.92, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -2,126.06, indicating conservative leverage, while an interest coverage ratio of -21.99 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Pacific Biosciences of California, Inc.'s stock has gained approximately 8% over the past 52 weeks. The 50-day moving average sits at 1.40, while the 200-day moving average is 1.64.

Income Statement

Over the trailing twelve months, Pacific Biosciences of California, Inc. generated 159.27M in revenue and converted that into -131.39M in net income, yielding earnings per share of -0.43. EBITDA reached -161.20M, while operating income came in at -178.84M.

Balance Sheet

Pacific Biosciences of California, Inc. holds 236.87M in cash and equivalents against 706.13M in total debt, resulting in a net debt position of 583.33M. Total book value stands at -33.21M, with working capital of 269.83M providing operational flexibility.

Cash Flow

Pacific Biosciences of California, Inc. produced -118.05M in operating cash flow over the past twelve months. After subtracting -12.43M in capital expenditures, free cash flow totaled -130.48M - equivalent to -0.43 per share.

Margins

Pacific Biosciences of California, Inc. operates with a gross margin of 36.38, reflecting its pricing power and cost economics. The operating margin of -112.28 and net profit margin of -82.49 provide insight into operational efficiency.

Dividends & Yields

Scores

Pacific Biosciences of California, Inc. posts an Altman Z-Score of -8.99, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.